137 related articles for article (PubMed ID: 38539054)
21. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.
Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L
World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470
[TBL] [Abstract][Full Text] [Related]
22. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
[TBL] [Abstract][Full Text] [Related]
23. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
24. Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma.
Kondo M; Ishizawa T; Enooku K; Tokuhara Y; Ohkawa R; Uranbileg B; Nakagawa H; Tateishi R; Yoshida H; Kokudo N; Koike K; Yatomi Y; Ikeda H
Clin Chim Acta; 2014 Jun; 433():128-34. PubMed ID: 24642343
[TBL] [Abstract][Full Text] [Related]
25. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
[TBL] [Abstract][Full Text] [Related]
26. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
27. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
Tada T; Toyoda H; Yasuda S; Miyake N; Kumada T; Kurisu A; Ohisa M; Akita T; Tanaka J
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1452-1459. PubMed ID: 31082998
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report.
Shan C; Yin GQ; Wu P
J Med Case Rep; 2014 Aug; 8():281. PubMed ID: 25146249
[TBL] [Abstract][Full Text] [Related]
29. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A
J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498
[TBL] [Abstract][Full Text] [Related]
30. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma.
Baran B
World J Hepatol; 2015 Jul; 7(13):1742-54. PubMed ID: 26167247
[TBL] [Abstract][Full Text] [Related]
31. Elevated Autotaxin and LPA Levels During Chronic Viral Hepatitis and Hepatocellular Carcinoma Associate with Systemic Immune Activation.
Kostadinova L; Shive CL; Anthony DD
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31769428
[TBL] [Abstract][Full Text] [Related]
32. Comparison of hepatitis B virus genotypes B and C among chronically hepatitis B virus-infected patients who received nucleos(t)ide analogs: A multicenter retrospective study.
Inoue J; Akahane T; Nakayama H; Kimura O; Kobayashi T; Kisara N; Sato T; Morosawa T; Izuma M; Kakazu E; Ninomiya M; Iwata T; Takai S; Nakamura T; Sano A; Niitsuma H; Masamune A;
Hepatol Res; 2019 Nov; 49(11):1263-1274. PubMed ID: 31254482
[TBL] [Abstract][Full Text] [Related]
33. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.
Rapti I; Hadziyannis S
World J Hepatol; 2015 May; 7(8):1064-73. PubMed ID: 26052395
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus.
Kim SK; Fujii T; Kim SR; Nakai A; Lim YS; Hagiwara S; Kudo M
Liver Cancer; 2022 Dec; 11(6):497-510. PubMed ID: 36589728
[TBL] [Abstract][Full Text] [Related]
35. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
[TBL] [Abstract][Full Text] [Related]
37. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Viganò M; Mangia G; Lampertico P
Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
[TBL] [Abstract][Full Text] [Related]
38. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
[TBL] [Abstract][Full Text] [Related]
39. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
40. Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naïve chronic hepatitis B patients.
Zhang Q; Li G; Yu Y; Qiu C; Zheng J; Zhang H; Zhang M; Song Z; Yang Y; Du X; Hong J; Lu J; Li N; Tang Q; Xu L; Wang X; Huang Y; Zhang J; Chen Z; Zhang W
J Viral Hepat; 2019 Jul; 26 Suppl 1():59-68. PubMed ID: 31380588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
